Myopia management at Roman Wagner in Schweich
Nothing is more important than the health and well-being of your child. Actively counteract the progression of nearsightedness.
Global prevalence of myopia
By 2050, it is estimated that 5 billion people, or 50% of the world’s population, will be affected by nearsightedness [1]. This condition is increasingly beginning in childhood.
The innovative MiYOSMART spectacle lens for myopia management in children and adolescents can slow the progression of nearsightedness by an average of 60% [2] or bring it to a complete standstill.
What is nearsightedness (myopia)?
Myopia is a congenital or acquired visual impairment. It occurs, among other things, when the eye grows too quickly and becomes excessively long. In this case, light rays are focused in front of the retina instead of on it. Nearsighted people see distant objects unclearly and blurred, while they can recognize near objects without any problems. An eye test results in negative diopter values, e.g., -1.50 dpt.
Why is nearsightedness increasing
in children?
Nearsightedness is highly likely to continue increasing due to growing digitalization and changes in children’s lifestyles.[3,4] Children use digital devices more, read and learn on PCs, and thus engage in more activities in the near-vision range. At the same time, they spend less time outdoors. Studies show that more time spent outdoors can significantly reduce the risk of nearsightedness.[5]
Genetic predisposition (e.g., nearsightedness of the parents) also plays a role in myopia.[1]
If nearsightedness in children and adolescents is not corrected, it can lead to permanent visual impairment.
MiYOSMART spectacle lenses counteract
myopia
MiYOSMART is the first non-invasive solution specifically developed as a spectacle lens to slow down myopia in children and adolescents between 6 and 18 years of age. A two-year clinical study shows that these special lenses can slow the progression of nearsightedness by an average of 60% [1], thereby protecting your children’s quality of vision and well-being in the long term.
How MiYOSMART works
The MiYOSMART spectacle lens corrects nearsightedness in the central zone like a normal single-vision lens. This means: if your child’s eye test showed a nearsightedness of -1.00 diopters, the MiYOSMART lens has -1.00 diopters in the central zone.
The surrounding D.I.M.S. area contains tiny segments of +3.5 diopters each. This ensures that eye length growth is not excessively stimulated, thus slowing the progression of myopia. D.I.M.S. stands for “Defocus Incorporated Multiple Segments.”
The special nature of the lenses is only visible in backlight or upon closer inspection. Otherwise, the lenses do not look any different from a normal single-vision lens to outsiders.
For the safety of children, MiYOSMART spectacle lenses are particularly impact-resistant, durable, easy to clean, and offer 100% UV protection. Only certified opticians and ophthalmologists work with MiYOSMART spectacle lenses.
Schedule an appointment in Schweich now at Tel. +49 6502 91410 or online here:
Information on increased risk applies to: 1 -3.5 to -6 dpt [5]; 2 <-3 dpt [6]; 3 <-3 dpt [7]; 4 -3 to -5 dpt [8]
Literature
[1] Holden BA et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036–42.
[2] Lin LLK et al. Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singap. 2004;33(1):27–33.
[3] Dolgin E. The myopia boom. Nature. 2015;519(7543):276–8.
[4] Flitcroft DI et al. IMI – Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20–30.
[5] Lim R, Mitchell P, Cumming RG. Refractive associations with cataract: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci. 1999;40(12):3021–6.
[6] Mitchell P et al. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology. 1999;106(10):2010–5.
[7] Eye Disease Case-Control Study Group. Risk factors for idiopathic rhegmatogenous retinal detachment. Am J Epidemiol. 1993;137(7):749–57.
[8] Vongphanit J, Mitchell P, Wang JJ. Prevalence and progression of myopic retinopathy in an older population. Ophthalmology. 2002;109(4):704–11.
[9] Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31(6):622–60.
[10] Saw S-M et al. Myopia and associated pathological complications. Ophthalmic Physiol Opt. 2005;25(5):381–91.
[11] Rose KA et al. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008;115(8):1279–85.
[12] Rose KA et al. Myopia, lifestyle, and schooling in students of Chinese ethnicity in Singapore and Sydney. Arch Ophthalmol. 2008;126(4):527–30.
[13] Wu P-C et al. Myopia prevention and outdoor light intensity in a school-based cluster randomized trial. Ophthalmology. 2018;125(8):1239–50.
[14] Wu P-C. The role of time outdoors in myopia onset and progression in schoolchildren from ROCT study. Invest Ophthalmol Vis Sci. 2019;60(9):3297–3297.
[15] Xiong S et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017;95(6):551–66.
[16] Wildsoet CF et al. IMI – Interventions for controlling myopia onset and progression report. Invest Ophthalmol Vis Sci. 2019;60(3):M106–31.
[17] Lam CSY et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363–8.
[19] Chia A, Lu Q-S, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology. 2016;123(2):391–9.
[20] Chia A et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347–54.
[21] Yam JC et al. Low-concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126(1):113–24.
[22] Tran HDM et al. A review of myopia control with atropine. J Ocul Pharmacol Ther. 2018;34(5):374–9.
[23] Cheng D et al. Effect of bifocal and prismatic bifocal spectacles on myopia progression in children: three-year results of a randomized clinical trial. JAMA Ophthalmol. 2014;132(3):258–64.
[24] Chamberlain P et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019;96(8):556–67.
[26] Swarbrick HA, Wong G, O’Leary DJ. Corneal response to orthokeratology. Optom Vis Sci. 1998;75(11):791–9.
[27] Charman WN et al. Peripheral refraction in orthokeratology patients. Optom Vis Sci. 2006;83(9):641–8.
[28] Kang P, Swarbrick H. Peripheral refraction in myopic children wearing orthokeratology and gas-permeable lenses. Optom Vis Sci. 2011;88(4):476–82.
[29] Cho P, Cheung S-W. Retardation of Myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci. 2012;53(11):7077–85.
[30] Santodomingo-Rubido J et al. Long-term efficacy of orthokeratology contact lens wear in controlling the progression of childhood myopia. Curr Eye Res. 2017;42(5):713–20.
Photos: © HOYA LENS SWITZERLAND AG